SavedAdd your journal

Journals / Retina-Vitreus / 2020 / Cilt: 29 - Sayı: 2

Intravitreal Dexamethasone Implant in the Treatment of Pseudophakic Cystoid Macular Edema or Irvine-Gass Syndrome

Havva KALDIRIM
Atalay KÜRŞAT
Şenay AŞIK NACAROĞLU
Serpil YAZGAN
Ahmet KIRGIZ
Pages
105–110
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

At 6th month and 12th month IOP values not signifi cantly different at baseline(p=0.506, p=0.650).Conclusion: Both BCVA and mean CMT had signifi cantly improved from baseline values after treatment with single doz intravitreal DEXimplant in patients with IGS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the effectiveness of intravitreal injections of dexamethasone (DEX) implant in patients with pseudophakic cystoidmacular edema (PCME) or Irvine-Gass Syndrome (IGS).Material and Methods: Patients with ME secondary to uncomplicated cataract surgery who underwent single intravitreal injections of DEXimplant from January 2015 to January 2017 were retrospectively reviewed.
📊
Key Findings & Data:The patients were examined at base-line and day 1, week 1, month1, 3, 6 and 12 after intravitreal injection.
💡
Conclusion & Impact:At 6th month and 12th month IOP values not signifi cantly different at baseline(p=0.506, p=0.650).Conclusion: Both BCVA and mean CMT had signifi cantly improved from baseline values after treatment with single doz intravitreal DEXimplant in patients with IGS.
🔬Design:Experimental Field Trial
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Özet

Purpose: To evaluate the effectiveness of intravitreal injections of dexamethasone (DEX) implant in patients with pseudophakic cystoidmacular edema (PCME) or Irvine-Gass Syndrome (IGS).Material and Methods: Patients with ME secondary to uncomplicated cataract surgery who underwent single intravitreal injections of DEXimplant from January 2015 to January 2017 were retrospectively reviewed. The patients were examined at base-line and day 1, week 1, month1, 3, 6 and 12 after intravitreal injection. All patients underwent a complete ophthalmic evaluation, including biomicroscopy, best-correctedvisual acuity (BCVA), intraocular pressure by applanation tonometry, and central macular thickness (CMT) measurement with a spectraldomainoptical coherence tomography (SD-OCT).Results: Nineteen eyes of 18 patients were evaluated. The alteration of mean BCVA and CMT were statistically signifi cantly better than baselinevalues at fi rst, third, sixth and twelfth months (p< 0.001). At 1st week, 1st month and 3rd month intraocular pressure (IOP) values signifi cantlyhigher than baseline (p=0.001, p=0.006, p=0.001, respectively). At 6th month and 12th month IOP values not signifi cantly different at baseline(p=0.506, p=0.650).Conclusion: Both BCVA and mean CMT had signifi cantly improved from baseline values after treatment with single doz intravitreal DEXimplant in patients with IGS.

🔖

Cite This Article

KALDIRIM, H., KÜRŞAT, A., NACAROĞLU, Ş. A., YAZGAN, S., KIRGIZ, A. (2020). Intravitreal Dexamethasone Implant in the Treatment of Pseudophakic Cystoid Macular Edema or Irvine-Gass Syndrome. Retina-Vitreus, Cilt: 29 - Sayı: 2, 105–110. https://ajindex.com/articles/340333

References (16)

  1. Lobo C. Pseudophakic cystoid macular edema. Ophthalmologica 2012; 227: 61–67
  2. Joussen A, Wolfensberger T. Mechanisms of macular edema and therapeutic approaches. In Ryan SJ (ed), Retina, 5th edn. Elsevier: New York, NY, USA, 2013, pp 590–594
  3. Bhattacherjee P. The role of arachidonate metabolites in ocular infl ammation. Prog Clin Biol Res 1989; 312:211–227
  4. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 1998; 96: 557–634
  5. Bergman M, Laatikainen L. Cystoid macular oedema after complicated cataract surgery and implantation of an anterior chamber lens. Acta Ophthalmol (Copenh) 1994; 72: 178– 180
  6. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002; 47(Suppl. 1): S203–18
  7. Flach AJ, Stegman RC, Graham J et al. Prophylaxis of aphakic cystoid macular edema without corticosteroids. Apaired-comparison, placebo-controlled double-masked study. Ophthalmology 1990; 97:1253–8
  8. Cox SN, Hay E, Bird A. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol 1988; 106:1190–5
  9. Sivaprasad S, Bunce C, Wormland R. Non-steroidal antiinfl ammatory agents for cystoid macular edema following cataract surgery: a systematic review. Br J Ophthalmol2005; 89:1420–2
  10. Benhamou N, Massin P, Haouchine B et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 2003; 135:246–9
  11. Barone A, Russo V, Prascina F et al. Short-term safety and effi cacy of intravitreal bevacizumab for pseudophakic cystoid macular edema. Retina (Philadelphia, Pa) 2009; 29:33–36
  12. Haller J.A., Bandello F., Belfort R et al. Randomized, shamcontrolled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: pp. 1134–1146
  13. Hunter RS, Lobo AM. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol. 2011; 5:1613–1621
  14. Haller J.A, Kuppermann B.D, Blumenkranz M.S et al: Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128: pp. 289–296
  15. Lazic R, Lukic M, Boras I et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina 2014; 34: pp. 719–724
  16. Catier A, Tadayoni R, Massin P et al. Advantages of acetazolamide associated with a